Julia Onken1,2, Franziska Staub-Bartelt1, Peter Vajkoczy1, Martin Misch3. 1. Department of Neurosurgery, Universitätsmedizin Charité Berlin, Charitéplatz 1, 10117, Berlin, Germany. 2. Berlin School of Integrative Oncology (BSIO), Berlin, Germany. 3. Department of Neurosurgery, Universitätsmedizin Charité Berlin, Charitéplatz 1, 10117, Berlin, Germany. martin.misch@charite.de.
Abstract
BACKGROUND: Tumor treating fields (TTFields) significantly prolong both progression-free and overall survival in patients with newly diagnosed glioblastoma (GBM). TTFields are delivered to the brain tumor via skin transducer arrays and should be applied for a minimum of 18 h per day (≥ 75% compliance). This may cause limited acceptance by patients because of obstacles in daily routine. So far, there are limited data on factors influencing therapy acceptance and compliance. METHODS: In this retrospective study, fourty-one patients with primary GBM or recurrent high grade glioma (rHGG) have been treated with TTFields in our department. Compliance reports were generated at the monthly routine check of the device. We investigated demographic data, stage of disease and therapy duration in regard to treatment compliance. RESULTS: Thirty percent of patients with primary diagnosis of GBM were informed about TTFields. Acceptance rate among these patients was 36%. In this study, TTFields were prescribed in newly diagnosed GBM patients (57%) and in rHGG. Mean treatment compliance was 87% in the total population independent of age, sex and stage of disease. Compliance was not negatively correlated with time on treatment. CONCLUSION: TTFields are effective in newly diagnosed GBM, therefore acceptance and compliance is important for GBM treatment. We experienced moderate acceptance rate for TTFields, which is influenced by factors such as social support, comorbidities and independence in daily life. Overall therapy compliance lies above 75% and is not influenced by age, sex, stage of disease or duration of therapy. Improved patient consultation strategies will increase acceptance and compliance for better outcome.
BACKGROUND: Tumor treating fields (TTFields) significantly prolong both progression-free and overall survival in patients with newly diagnosed glioblastoma (GBM). TTFields are delivered to the brain tumor via skin transducer arrays and should be applied for a minimum of 18 h per day (≥ 75% compliance). This may cause limited acceptance by patients because of obstacles in daily routine. So far, there are limited data on factors influencing therapy acceptance and compliance. METHODS: In this retrospective study, fourty-one patients with primary GBM or recurrent high grade glioma (rHGG) have been treated with TTFields in our department. Compliance reports were generated at the monthly routine check of the device. We investigated demographic data, stage of disease and therapy duration in regard to treatment compliance. RESULTS: Thirty percent of patients with primary diagnosis of GBM were informed about TTFields. Acceptance rate among these patients was 36%. In this study, TTFields were prescribed in newly diagnosed GBM patients (57%) and in rHGG. Mean treatment compliance was 87% in the total population independent of age, sex and stage of disease. Compliance was not negatively correlated with time on treatment. CONCLUSION: TTFields are effective in newly diagnosed GBM, therefore acceptance and compliance is important for GBM treatment. We experienced moderate acceptance rate for TTFields, which is influenced by factors such as social support, comorbidities and independence in daily life. Overall therapy compliance lies above 75% and is not influenced by age, sex, stage of disease or duration of therapy. Improved patient consultation strategies will increase acceptance and compliance for better outcome.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Aafia Chaudhry; Laura Benson; Michael Varshaver; Ori Farber; Uri Weinberg; Eilon Kirson; Yoram Palti Journal: World J Surg Oncol Date: 2015-11-11 Impact factor: 2.754
Authors: Ryan Miller; Andrew Song; Ayesha Ali; Muneeb Niazi; Voichita Bar-Ad; Nina Martinez; Jon Glass; Iyad Alnahhas; David Andrews; Kevin Judy; James Evans; Christopher Farrell; Maria Werner-Wasik; Inna Chervoneva; Michele Ly; Joshua Palmer; Haisong Liu; Wenyin Shi Journal: Front Oncol Date: 2022-04-29 Impact factor: 5.738
Authors: Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp Journal: Oncology (Williston Park) Date: 2019-03-13 Impact factor: 2.990
Authors: Aleksandrs Krigers; Daniel Pinggera; Matthias Demetz; Lisa-Marie Kornberger; Johannes Kerschbaumer; Claudius Thomé; Christian F Freyschlag Journal: Front Neurol Date: 2022-06-16 Impact factor: 4.086